SeaStar Medical (ICU) Investor presentation summary

Mission and value proposition

• Aims to stop organ failure and save lives by neutralizing destructive hyperinflammation.

• SCD therapy is agnostic to disease state and protected by 34 U.S. and foreign patents.

• Focus on expanding indications, maximizing market penetration, and driving stakeholder value.

• High gross profit margin and efficient commercialization strategy.

Market opportunity and clinical need

• Adult AKI market in the U.S. is valued at ~$4.5B with over 200,000 patients annually; pediatric AKI market is ~$100M.

• Critically ill AKI patients have mortality rates exceeding 50% and high risk of chronic disease.

• CMS assigned ICD-10-PCS codes effective October 2026, enabling standardized billing and supporting rapid adoption.

Technology and mechanism of action

• SCD therapy targets the upstream source of cytokine production, neutralizing activated neutrophils and monocytes.

• Integrates with existing renal replacement therapy in ICUs, restoring homeostasis by deactivating effector cells.

• First and only therapy to neutralize destructive hyperinflammation, addressing redundancy in immune response.